Eyenovia, Inc. (NASDAQ:EYEN) Q4 2022 Earnings Call Transcript
Operator: Greetings, and welcome to the Eyenovia Fourth Quarter and Full Year 2022 Earnings Call. As a reminder, this conference is being recorded.
Source: insidermonkey.com
Page 5 - Eric Ribner News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Eric Ribner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Eric Ribner Today - Breaking & Trending Today
Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update
30.03.2023 - Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May 8, 2023 Announced positive results from Microline Phase 3 program as a potential treatment for presbyopia and received feedback from the FDA outlining a ...
Source: wallstreet-online.de
Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers
Nes-Ziona, Israel, March 20, 2023 -- Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company, today announced that an independent Data and Safety Monitoring... | March 20, 2023
Source: marketscreener.com
Small Pharma Announces Further Positive Data from SPL026
-Patients’ self-reported depression and wellbeing scores corroborate MADRS efficacy data-Statistically significant improvement in anxiety symptoms offers...
Source: globenewswire.com
Small Pharma Inc.: Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder
First placebo-controlled efficacy study completed to date exploring a short-duration psychedelic for depression demonstrates rapid and durable response Primary endpoint met with a statistically significant
Source: finanznachrichten.de